Earnings ·
PDS Biotechnology Corporation reported a net loss of $9.8 million, or $0.18 per share, for the quarter ended June 30…
PDSBPDS Biotechnology Corp
PDS Biotechnology Corporation reported a net loss of $9.8 million, or $0.18 per share, for the quarter ended June 30, 2026, compared to a $9.4 million loss in the prior year period. The company announced a strategic refocus to prioritize PDS0301 as its lead development program and ceased internal investment in PDS0101, including discontinuing the VERSATILE-003 Phase 3 trial. R&D expenses decreased to $3.3 million from $4.2 million, while net interest expense increased to $3.3 million due to a non-cash charge for debt retirement. Cash balances declined to $5.6 million from $26.7 million at year-end. The company operates in the biotechnology industry, developing targeted immunotherapies for cancer.